Patentee Failed to Apportion Licenses to Bundled Patents to Establish Royalties
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
OMEGA PATENTS, LLC v. CALAMP CORPORATION
Before Prost, Dyk, and Hughes. Appeal from the United States District Court for the Middle District of Florida.
Summary: Licensing policies that allow use of any or all of a bundle of patents for a single per-unit fee are not a proper basis for establishing royalties without apportionment.
Omega sued CalAmp for direct infringement and induced infringement of various claims across four separate patents. During the jury trial, Omega introduced multiple licenses and presented evidence that its policy was to negotiate a license for “five dollars [per unit,] whether it’s one patent or 50 patents.” The jury found that CalAmp directly infringed and awarded Omega royalties of $5 per unit. CalAmp moved for a new trial on damages, arguing that Omega’s damages theory was legally flawed and unsupported by the evidence. The district court denied CalAmp’s motion.
The Federal Circuit reversed and remanded for a new trial on damages. To prove damages, the patentee must provide evidence that apportions the damages between the patented features and the unpatented features of an accused product. The Federal Circuit held that the patentee failed to show that the patented feature drove demand for the accused product and also failed to show the incremental value that the patented feature added to the accused product. The Federal Circuit then turned to the patentee’s comparable license theory. The Federal Circuit held that Omega failed to adequately account for the differences between the licenses charging $5 per unit for multiple patents and a hypothetical negotiation on a single patent.
Judge Hughes dissented, arguing that Omega’s licenses and its licensing policy were sufficient to support the jury award.
Editor: Paul Stewart
Written by: Kendall Loebbaka
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…